Goldman Sachs Group Inc. boosted its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 3.7% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 339,936 shares of the specialty pharmaceutical company’s stock after buying an additional 12,263 shares during the quarter. Goldman Sachs Group Inc.’s holdings in KalVista Pharmaceuticals were worth $3,923,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Earned Wealth Advisors LLC acquired a new stake in KalVista Pharmaceuticals during the first quarter worth about $44,000. GAMMA Investing LLC lifted its position in shares of KalVista Pharmaceuticals by 567.3% in the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company’s stock valued at $51,000 after acquiring an additional 3,767 shares in the last quarter. CWM LLC lifted its position in shares of KalVista Pharmaceuticals by 12,636.1% in the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock valued at $53,000 after acquiring an additional 4,549 shares in the last quarter. Quarry LP purchased a new position in shares of KalVista Pharmaceuticals in the first quarter valued at approximately $97,000. Finally, Ieq Capital LLC purchased a new position in shares of KalVista Pharmaceuticals in the first quarter valued at approximately $126,000.
Get KalVista Pharmaceuticals alerts:
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the company. HC Wainwright raised their target price on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, July 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, September 12th. JMP Securities increased their price target on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a report on Friday, September 12th. Finally, Leerink Partners increased their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Monday, July 7th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $26.43.
Read Our Latest Stock Report on KalVista Pharmaceuticals
Insider Transactions at KalVista Pharmaceuticals
In other news, insider Paul K. Audhya sold 2,336 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $13.42, for a total transaction of $31,349.12. Following the sale, the insider owned 122,505 shares in the company, valued at approximately $1,644,017.10. The trade was a 1.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 7,294 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $15.84, for a total value of $115,536.96. Following the sale, the chief executive officer owned 395,189 shares in the company, valued at $6,259,793.76. This trade represents a 1.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,835 shares of company stock worth $892,350 in the last quarter. Insiders own 4.30% of the company’s stock.
KalVista Pharmaceuticals Price Performance
Shares of NASDAQ KALV opened at $13.38 on Thursday. The company has a market capitalization of $675.96 million, a price-to-earnings ratio of -3.40 and a beta of -0.10. The business has a 50-day moving average of $14.03 and a two-hundred day moving average of $12.84. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $17.28.
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last posted its earnings results on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.21). The firm had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.97 million. As a group, equities research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.
KalVista Pharmaceuticals Company Profile
(Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
See Also
Five stocks we like better than KalVista Pharmaceuticals
What is an Earnings Surprise?
Biotech Breakouts: 3 Stocks With Massive Upside Potential
Conference Calls and Individual Investors
Powering Up: A Buy Rating Signals GE Vernova’s AI Tailwinds
How Technical Indicators Can Help You Find Oversold Stocks
The Side of Rate Cuts Nobody Is Telling You About
Want to see what other hedge funds are holding KALV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report).
